The potential of microRNAs (miRNAs) 7 as biomarkers on the basis of tissue or body fluids is increasingly recognized. Since their discovery, miRNA profiles from serum, plasma, or blood cells have been generated and statistically evaluated for a multitude of human pathogenic processes, including almost all cancer entities but also many noncancer diseases, such as multiple sclerosis, acute myocardial infarction, Alzheimer disease, and chronic obstructive pulmonary disease (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
The majority of the existing biomarker studies have been carried out by use of case-control designs. One would expect that matching of both groups for confounding factors in these studies was a prerequisite. However, biomaterials from existing retrospective cohorts often do not meet the high requirements for RNA-based molecular analysis, and the buildup of adequately large matched disease and control cohorts can be problematic. Especially in diseases effecting elderly persons, it can be highly challenging to recruit suitable healthy control cohorts of the same age distribution. Consequently, many published studies fail to match the 2 most basic confounders, age and sex.
The influence of these fundamental confounding variables, age and sex, on miRNA profiles from bodily fluids has not been fully explored. However, various miRNAs are known to exert key roles in aging, and other miRNAs are encoded on sex chromosomes (12 ) , which already suggests that a relevant portion of human miRNA profiles will depend on the age and sex distribution of samples. In our analysis, we systematically investigated the influence of age and sex on miRNA profiles in a large cohort of physiologically un-affected individuals. We detected a statistically significant number of miRNAs that were influenced by age or sex of the respective individuals. We validated our initial findings using an independent cohort of 58 samples from physiologically unaffected controls by applying high-throughput sequencing.
Materials and Methods

STUDY DESIGN AND BLOOD SAMPLE COLLECTION
In this study, we included 109 physiologically unaffected individuals (stage 1), whose blood has been partially measured as part of the human bloodborne miRNome project (1 ) . This collection contains whole miRNome-wide measurements according to Sanger miRBase (13, 14 ) version 14, for 454 samples. The remaining control samples have been included in the second version of the human bloodborne miRNome project, containing a total of 1050 samples measured by the same microarray technology. In a second cohort (stage 2), we measured an additional 58 physiologically unaffected controls using an independent technology, highthroughput sequencing on Illumina HiSeq 2000.
All blood samples were collected by use of a standard operating procedure in PAXgene Blood RNA tubes (Becton Dickinson). All blood donors participating in this study provided written informed consent, and the local ethics committee approved the study.
miRNA EXTRACTION AND MICROARRAY SCREENING (STAGE 1)
We carried out miRNA extraction and microarray measurement as previously described (1 ). In brief, 2.5-5 mL of venous blood was collected in PAXgene Blood RNA tubes. Total RNA, including small RNAs, was extracted and stored at Ϫ70°C. All samples of stage 1 were screened by use of the Geniom RT Analyzer system (Febit Biomed) with the Geniom Biochip miRNA Homo sapiens covering 848 common miRNAs in versions 12-14 of the Sanger miRBase. Each miRNA was represented by at least 7 replicated features on the microarray; for each miRNA, the median signal intensity was calculated.
HIGH-THROUGHPUT SEQUENCING (STAGE 2)
For library preparation, we used 70 ng total RNA per sample, as determined with a RNA 6000 Pico Chip on the Bioanalyzer 2100 (Agilent). For preparation, we used the TruSeq Small RNA Sample Prep Kit (Illumina). Ready prepped libraries were measured with the Bioanalyzer by use of the DNA 1000 Chip and subsequently pooled in batches of 6 samples in equal amounts. Sequencing libraries were then clustered with a final concentration of 9 pmol in 1 lane each of a single-read flow cell by use of the cBot instrument (Illumina). Sequencing of 50 cycles was performed on a HiSeq 2000 (Illumina). Demultiplexing of the raw sequencing data and generation of the fastq files was done with CASAVA version 1.8.2.
BIOSTATISTICAL ANALYSIS
To account for variations between different microarrays, we applied standard quantile normalization to the raw expression intensities. All downstream analyses were carried out on the normalized intensity values. We performed all bioinformatics calculations using the free and publicly available statistical language R (http:// www.r-project.org/), if not mentioned otherwise.
For next-generation sequencing (NGS) data analysis, we preprocessed the raw Illumina reads by cutting the 3Ј adapter sequence by use of the program fastx_ clipper from the FASTX-Toolkit. After that, we used the miRDeep2 pipeline using the standard parameters for retrieving the miRBase counts for release version 20 and prediction of novel miRNAs. We applied HG20 as the reference genome for this analysis. Because the microarray experiments were measured by use of previous miRBase versions, whereas high-throughput sequencing results relied on the most recent version of the miRBase, we used the sequence of miRNAs as unique identifiers to match between the different miRBase versions.
To assess significance values for quantifying differences between males and females, we applied the parametric unpaired two-tailed t-test after verifying that data were approximately normally distributed by use of the Shapiro-Wilk test. To compute significance values for correlation coefficients, we applied test statistics on the basis of Pearson's product-moment correlation coefficient. Cluster analysis was carried out by use of R. Hierarchical clustering on the basis of the Bioconductor package Heatplus was applied to calculate heat maps and dendrograms. The hclust and cuttree functions were used to extract clusters out of the dendrogram. By use of this clustering information, contingency tables were generated, and Fisher test was applied to calculate significance values.
WEB SERVICE
To make the calculations available for other researchers, we implemented a web-based tool that is freely available for noncommercial usage (http://www. ccb.uni-saarland.de/mirnacon). Our tool receives as input either the IDs of a set of miRNAs along with the respective miRBase version or a set of miRNA sequences. These sequences are then matched to the most recent version 20 of miRBase and mapped to our experimental data. For further input parameters, the user can select the significance threshold (standard value 0.05) and a lower boundary for significance values (standard value 0.001). This boundary is just applied for the graphical representation of the results, i.e., miRNAs with significance below this value are presented at the cutoff. Because the analysis itself may be biased by different age distributions in the test set, users can input the mean age and SD of the study population used for their study. Our tool then automatically extracts a subcohort of our samples that best matches the user's age distribution.
For output, our tool generates a scatterplot showing the background distribution of miRNAs in our study (gray dots); the miRNAs uploaded by the user (red dots); and whether the miRNAs are not influenced by age and sex (green area of the scatter plot), influenced by either age or sex (gray area of the scatter plot), or influenced by age and sex (red area of the scatter plot). Furthermore, we generate a tabular output containing the uploaded ID, the respective sequence, the ID in the most recent version 20 of the Sanger miRBase, and whether this miRNA is influenced by age and/or sex.
Results
We included a total of 109 controls in the microarraybased miRNA assessment of stage 1. The miRNA biomarkers were profiled by use of miRNA microarrays covering 848 miRNAs across versions 12-14 of the Sanger miRBase. The cohort contained samples from 65 women and 44 men with a mean age of 57.3 (SD 25.5) years, range 19 -105 years.
Likewise, 58 independently collected and measured controls were processed by use of highthroughput sequencing and mapped to miRBase version 20. The cohort contained 12 women and 46 men. Considering age, the individuals in the second cohort had a similar mean age as the stage 1 cohort (58.3 years); however, this cohort had a much smaller age variance (SD 8.6 years, range 44 -75 years). Age distribution metrics for both cohorts are provided in Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/ vol60/issue9.
IMPACT OF AGE ON miRNA PROFILES
First, we calculated the correlation of each miRNA to the age of the individuals, providing us with 848 different correlation coefficients. Additionally, we calculated significance values for the respective correlations and considered unadjusted as well as adjusted P values (Bonferroni adjustment). Of the 848 miRNAs, 318 were significantly correlated with age (raw P value of Ͻ0.05). Notably, around one-third (107) were negatively correlated with age, whereas two-thirds (211) were positively correlated with age. This shift in the distribution toward positive correlation can be seen in Fig. 1 (right side of the histogram). In this figure, all miRNAs with a correlation coefficient Ͼ0.5 are given. Notably, even after adjustment for multiple testing by use of the conservative Bonferroni approach, 35 miRNAs remained significant (adjusted P value Ͻ0.05). The 35 miRNAs along with the raw significance values and the correlation coefficients are detailed in Table 1 .
Regarding the stage 2 cohort with a more narrow age distribution but comparable mean age, we calculated a substantially smaller amount of significantly associated miRNAs. Whereas the stage 1 cohort quartiles are 34, 57.5, and 71 years, the validation cohort quartiles are 53, 56, and 65 years. Despite these differences, we observed 7 of the originally detected miRNAs that were expressed and significantly correlated with age in the second cohort. Of these 7 miRNAs, 5 showed the same direction of dysregulation as in stage 1. The miRNAs significantly influenced by age in both stages include hsa-miR-1284, hsa-miR-93-3p, hsa-miR-1262, hsa-miR-34a-5p, and hsa-miR-145-5p, meaning that these miRNAs may be most strongly affected by aging. The markers are summarized in Table 2 together with the respective correlation values. Fig. 2 shows scatter plots for the most significantly downregulated miRNA, namely hsa-miR-106a, and the miRNA with the best fit between microarrays and NGS, hsa-miR-93-3p. Each image shows a significant positive or negative correlation of miRNA expression with age of individuals, respectively.
Next, we investigated the dependency of agemiRNA correlations on the age distribution. To this end, for the 23 most significant correlations from Table  1 , we calculated the correlation for subcohorts with approximated mean age of 40, 50, 60, and 70 years. As the spider diagram in Fig. 3 shows, the significance for these miRNAs substantially changed with different subcohorts. The most significant results were detected for the subcohort with a mean age of 60 years, where 10 miRNAs were significantly correlated (inside of the gray-shaded area of the spider diagram). By contrast, for the 40-and 70-year subcohorts, just 2 of the miRNAs remained significant.
IMPACT OF SEX ON miRNA PROFILES
We also calculated significance values for the sex of all individuals. In this analysis, we detected much lower numbers of significantly associated miRNAs. Although 318 significant markers were found in stage 1 for age, we found only 144 miRNAs significant before adjustment for multiple testing in case of sex. Although this number is much higher than the expected number of significant miRNAs at an ␣ level of 0.05, no miRNA remained significant after Bonferroni adjustment (P value Ͻ0.05 after adjustment; smallest P value after adjustment: 0.09).
For stage 2, we calculated significantly different expression levels depending on sex for 6 of the differentially expressed miRNAs, with only 3 miRNAs (hsamiR-219a-1-3p, hsa-miR-548c-3p, and hsa-miR-130a-3p) being concordant in both cohorts, demonstrating that differences in miRNA were mainly due to the confounding factor age, but less to sex.
miRNA PATTERNS CLUSTER INDIVIDUALS REGARDING AGE AND SEX
In addition to the above correlation analysis, we carried out unsupervised and supervised cluster approaches. First, we extracted the 10 most variable miRNAs and calculated whether these miRNAs separate the individuals with respect to sex (male vs female) or age (young vs old, cutoff mean age). With respect to sex, we reached a significance value of 0.01 after separating the data into 2 clusters. With respect to age, we found an even more significant clustering with a P value of 0.0067, confirming our initial findings that the age of individuals has a larger impact on miRNA than their sex (see online Supplemental Fig. 1 ).
Additionally, we applied a supervised clustering approach. Here, we included the most significantly correlated miRNAs (raw P value Ͻ0.05) for the clustering, limiting the analysis, however, to the 50 miRNAs with highest data variance. As expected, the significance of the clustering substantially improved. With respect to age, the significance value went down to 0.0004; for sex, down to 0.0006 (see online Supplemental Figs. 2 and 3 ).
REPRESENTATION OF RESULTS AND WEB-BASED ANALYSIS
Because our results indicated a moderate influence of sex and a substantial influence of age on bloodborne miRNA profiles, we implemented a web-based solution for providing other researchers with easy access to the respective data and the ability to visualize the degree of influence of age and sex on candidate miRNA biomarkers of their studies. As input, users can choose between the miRNA sequence or miRBase miRNA IDs. For the latter, all versions starting from miRBase 16 are implemented. Furthermore, the user can specify a significance threshold as well as parameters for improved graphical representation. As demonstrated above, the overall age distribution has the highest impact on 
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miRNAs. Thus, users can also specify the average age and SD of their cohort. Our algorithm, which relies on the results of stage 1, then searches dynamically for a subcohort that matches the requested parameters of the user.
In the tabular output, the miRNA-ID is shown, as well as its mapping to the most recent ID in miRBase version 20 and the sequence of the miRNA. In the fourth and fifth column of the output table, the potential influence of age and sex are documented. We tested our tool on a hypothetical disease signature with 9 markers (chosen from studies on different diseases). Of these, 2 (miR-144 and miR-20b) are potentially influenced by age, whereas 7 (miR-1, miR-127-5p, miR-1270, miR-1271, miR-1272, miR-144*, and miR-20a*) are not influenced significantly. Fig. 4 presents the graphical output of the tool. The miRNAs in the upper right quadrant (green) are not significantly influenced. The miRNAs in the lower right quadrant are potentially influenced by age and thus highlighted by red points. The red-shaded lower right quadrant would contain miRNAs that are influenced by age and sex. All miRNAs uploaded by the user are shown as colored dots, and the distribution of the miRNAs from stage 1 of this study are represented by gray dots. The tool is freely available for noncommercial applications at http://www.ccb.uni-saarland.de/mirnacon/. Discussion miRNAs are increasingly recognized as biomarkers for various diseases, including almost all cancer entities and metabolic, neurological, and cardiovascular disorders. We investigated here the role of the confounding variables age and sex on the miRNA profiles observed in whole peripheral blood.
Despite the euphoria about the potential clinical application of miRNAs in disease detection and estimation of prognosis, many miRNA biomarkers show discrepant results in independent investigations of the same disease. In addition to technical challenges such as sample handling, RNA processing, and storage, as well as differences in the underlying measurement technology such as microarrays or high-throughput sequencing, many obstacles remain that could addition- Distribution of miRNA and age are presented above and on the right of the plots, respectively. On a logarithmic scale, the diagram presents the significance of correlation with the age for 4 age groups. The highest significance (closest proximity to the center) was detected for the age cohort of 60-year-old individuals.
ally affect this observation. In recent publications, some confounding factors for miRNAs from serum or plasma were found to include patient treatment (15 ) and comorbidities. However, the role of the fundamental confounders age and sex are only partially understood. We show here that age potentially has a higher influence on the expression of miRNAs than sex. Knowledge about the confounding factors and their influence on certain miRNAs has considerable consequences. First, a well-designed study with adequately sized case and control cohorts should be a prerequisite. However, often it is very challenging to have suitable control cohorts of healthy individuals matching the age distribution of cases. This is obviously most important when studying diseases of the elderly, such as neurodegenerative diseases or chronic heart failure. Another way to circumvent potential bias due to nonequally distributed variables would be the implementation of the findings presented here in statistical approaches to select appropriate subcohorts in silico, to use, e.g., the ages as additional input variables for Fig. 4 . Graphical output of miRNACon, the web service for dynamic calculation of potential confounding variables. x axis, P value for sex; y axis, P value for age. Gray dots belong to background miRNAs, green dots to user-specified miRNAs that seem to be not affected by sex and age, and red dots to affected miRNAs. machine-learning methods or to dynamically build models. A more straightforward approach would be to verify miRNAs by use of the provided online application and exclude strongly influenced candidates from the respective signatures.
Although we found age to be a strong confounder, all analyses revealed only a limited influence of sex on miRNA patterns. Nevertheless, we investigated the most differentially expressed miRNAs between males and females in more detail to support the hypothesis of sex-dependent miRNA regulation by comparing them to those experimentally affected by estrogen. We investigated blood cells, and the study by Maillot et al. (16 ) relied on breast cell cultures exposed to estrogen. They found 23 miRNAs that are significantly downregulated after estrogen signaling has been induced and thus depend indirectly on sex. Of these 23 miRNAs, 18 are expressed higher in males (78.3%) in our cohorts. Although these miRNAs were not significantly differentially expressed after adjustment for multiple testing, these results hint at a limited sexdependent miRNA signature in blood cells. Here, larger cohorts may reveal whether the differences are actually significant.
A challenge in generalizing our findings is technical variation between different platforms. Most frequently, array technology and NGS are applied to screen for mRNA or miRNA biomarkers, and quantitative reverse-transcription PCR is applied to validate the results. In 2010, Git et al. presented a technological evaluation (17 ) , concluding that the actual overlap between the platforms was low. As a consequence, our web service currently incorporates only the microarray data of the larger cohort with the higher age variation. The extension to NGS is planned for one of the succeeding versions, as well as to provide similar functionality for serum and plasma.
Another interesting observation of our study is that age-related miRNAs may also have biological meaning. For several miRNAs, animal studies could provide evidence for their role in senescence or antiaging. For instance, hsa-miRNA-34a was recently recognized as positively correlating with age, suppressing important downstream targets and leading to telomere shortening and cardiomyocyte dysfunction/apoptosis (12 ) . In line with these results, Li et al. describe miR34a as being upregulated in tissue and blood of older mice (18 ) . This makes miR-34a a good positive control for our study. Indeed, miR-34a is significantly correlated with age in our results (raw P value 0.0086). In contrast, Li et al. (18 ) describe miR-196a to be independent of age. Concordant with these results, this miRNA is not significantly regulated with age in our study (raw P value 0.08). Thus, miR-196a represents a valuable negative control for our study. The miRNAs correlating to age identified here might also harbor functional properties that are important for age research and represent potential pharmaceutical targets. Hence, our repertoire of miRNAs includes appealing targets for further functional workup.
In summary, our study provides evidence that especially age is an important confounding variable for miRNA biomarker profiles in human blood samples, whereas sex shows just a limited effect on bloodborne miRNA patterns. We make the results of this study available to researchers through an easy-to-use webbased tool. Clearly, there should be a focus on additional common confounders, such as smoking, kidney and liver function, and others, to systematically dissect their influence on miRNAs from body fluids and tissues. With these precautions, miRNAs have the potential to proceed into clinical application for many diseases that are currently difficult to diagnose. 
Role of Sponsor:
The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.
